Adjuvant-containing control arms in pivotal quadrivalent human papillomavirus vaccine trials: restoration of previously unpublished methodology
Saved in:
| Title: | Adjuvant-containing control arms in pivotal quadrivalent human papillomavirus vaccine trials: restoration of previously unpublished methodology |
|---|---|
| Authors: | Bourgeois, Florence, Hong, Kyungwan, Lee, Haeyoung, Shamseer, Larissa, Spence, O'Mareen, Jefferson, Tom, Doshi, Peter, Jones, Mark A., B.Sc., Ph.D. |
| Source: | BMJ Evidence-Based Medicine ; bmjebm ; 2019 |
| Publisher Information: | BMJ |
| Publication Year: | 2020 |
| Collection: | UMB Digital Archive (University of Maryland, Baltimore) |
| Subject Terms: | AAHS, amorphous aluminum hydroxyphosphate sulfate, qHPV, quadrivalent human papillomavirus vaccine, Restoring Invisible and Abandoned Trials, RIAT, Adjuvants, Pharmaceutic, Papillomavirus Vaccines, Placebos, Randomized Controlled Trials as Topic--ethics |
| Description: | Purpose: Trustworthy reporting of quadrivalent human papillomavirus (HPV) vaccine trials is the foundation for assessing the vaccine’s risks and benefits. However, several pivotal trial publications incompletely reported important methodological details and inaccurately described the formulation that the control arms received. Under the Restoring Invisible and Abandoned Trials initiative (RIAT), we aim to restore the public record regarding the content and rationale of the controls used in the trials. Methods: We assembled a cohort (five randomised controlled trials) described as placebo-controlled using clinical study reports (CSRs) obtained from the European Medicines Agency. We extracted the content and rationale for the choice of control used in each trial across six data sources: trial publications, register records, CSR synopses, CSR main bodies, protocols and informed consent forms. Results: Across data sources, the controlwas inconsistently reported as ‘placebo’- containing aluminium adjuvant (sometimes with dose information). Amorphous aluminium hydroxyphosphate sulfate (AAHS) was not mentioned in any trial registry entry, but was mentioned in all publications and CSRs. In three of five trials, consent forms described the control as an ‘inactive’ substance. No rationale for the selection of the control was reported in any trial publication, register, consent form, CSR synopsis or protocol. Three trials reported the rationale for choice of control in CSRs: to preserve blinding and assess the safety of HPV virus-like particles as the ‘safety profile of (AAHS) is well characterised’. Conclusions: The stated rationale of using AAHS control—to characterise the safety of the HPV virus-like particles—lacks clinical relevance. A nonplacebo control may have obscured an accurate assessment of safety and the participant consent process of some trials raises ethical concerns. Trial registration numbers NCT00092482, NCT00092521, NCT00092534, NCT00090220, NCT00090285. ; Laura and John Arnold Foundation ... |
| Document Type: | article in journal/newspaper |
| Language: | English |
| Relation: | BMJ Evidence-Based Medicine; http://hdl.handle.net/10713/13213 |
| DOI: | 10.1136/bmjebm-2019-111331 |
| Availability: | http://hdl.handle.net/10713/13213 https://doi.org/10.1136/bmjebm-2019-111331 |
| Rights: | http://creativecommons.org/licenses/by-nc/4.0/ |
| Accession Number: | edsbas.DFD72C5E |
| Database: | BASE |
Nájsť tento článok vo Web of Science | Abstract: | Purpose: Trustworthy reporting of quadrivalent human papillomavirus (HPV) vaccine trials is the foundation for assessing the vaccine’s risks and benefits. However, several pivotal trial publications incompletely reported important methodological details and inaccurately described the formulation that the control arms received. Under the Restoring Invisible and Abandoned Trials initiative (RIAT), we aim to restore the public record regarding the content and rationale of the controls used in the trials. Methods: We assembled a cohort (five randomised controlled trials) described as placebo-controlled using clinical study reports (CSRs) obtained from the European Medicines Agency. We extracted the content and rationale for the choice of control used in each trial across six data sources: trial publications, register records, CSR synopses, CSR main bodies, protocols and informed consent forms. Results: Across data sources, the controlwas inconsistently reported as ‘placebo’- containing aluminium adjuvant (sometimes with dose information). Amorphous aluminium hydroxyphosphate sulfate (AAHS) was not mentioned in any trial registry entry, but was mentioned in all publications and CSRs. In three of five trials, consent forms described the control as an ‘inactive’ substance. No rationale for the selection of the control was reported in any trial publication, register, consent form, CSR synopsis or protocol. Three trials reported the rationale for choice of control in CSRs: to preserve blinding and assess the safety of HPV virus-like particles as the ‘safety profile of (AAHS) is well characterised’. Conclusions: The stated rationale of using AAHS control—to characterise the safety of the HPV virus-like particles—lacks clinical relevance. A nonplacebo control may have obscured an accurate assessment of safety and the participant consent process of some trials raises ethical concerns. Trial registration numbers NCT00092482, NCT00092521, NCT00092534, NCT00090220, NCT00090285. ; Laura and John Arnold Foundation ... |
|---|---|
| DOI: | 10.1136/bmjebm-2019-111331 |